Revvity, Inc.
RVTY
Positions held
Your positionsRVTY isn't in your positions.
Add it to see shares, cost, and P&L here.
Bull / bear case
Site-generated summary from fundamentals, news, and score — not investment advice. As of 2026-10-07.
- Revvity, Inc. operates in the growing diagnostics and research sector, which is essential for advancing healthcare solutions and improving patient outcomes.
- Revenue increased by 3% from the prior quarter, reaching $730 million.
- Gross margin improved to 57.1%, up from 54.5% in the previous quarter.
- The company's trailing P/E ratio of 73.35 suggests that it may be overvalued compared to industry peers.
- Net income decreased to $51.82 million in Q2 2026, down from $98.36 million in Q4 2025.
- Operating margin contracted to 12% from 14.5% in the previous quarter.
Fundamentals
| Market cap | $16.98B | Enterprise value | $19.30B | Trailing P/E | 72.80 | Forward P/E | 25.82 |
| PEG | 0.73 | Price / book | 2.35 | Beta | 1.06 | Dividend yield | 0.18% |
| Revenue growth | 1.3% | Earnings growth | 1.2% | Gross margin | 55.0% | Operating margin | 17.1% |
| Profit margin | 8.2% | ROE | 3.2% | ROA | 2.4% | Debt / equity | 0.46 |
| Current ratio | 1.80 | Free cash flow | $604.99M | Analyst recommendation | buy | Mean target | $138.87 |
| 52w high | $166.25 | 52w low | $81.22 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $730M | $711M | $772M | $699M | $720M | — |
| Op margin | 12.0% | 10.7% | 14.5% | 11.7% | 12.4% | — |
| Net income | $51.8M | $40.7M | $98.4M | $46.7M | $53.9M | — |
| Gross margin | 57.1% | 54.5% | 54.6% | 53.6% | 54.5% | — |
| Gross profit | $417M | $388M | $422M | $375M | $393M | — |
| Operating income | $87.9M | $75.9M | $112M | $81.9M | $89.1M | — |
- Revenue +3% vs prior quarter ($730M vs $711M).
- Gross margin 57.1% (was 54.5% prior quarter).
- Operating margin expanded to 12%.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $2.9B | $2.8B | $2.8B | $3.3B | — |
| Op margin | 12.5% | 12.6% | 10.9% | 22.4% | — |
| Net income | $241M | $270M | $693M | $569M | — |
| Gross margin | 54.8% | 55.8% | 56.0% | 60.1% | — |
| Gross profit | $1.6B | $1.5B | $1.5B | $2.0B | — |
| Operating income | $357M | $347M | $301M | $743M | — |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-08 · Baird Adjusts Price Target on Revvity to $164 From $144
2026-10-07 · Evercore ISI Adjusts Revvity Price Target to $165 From $125
2026-10-07 · Revvity Earnings Preview: What to Expect
2026-10-06 · Barclays Adjusts Price Target on Revvity to $160 From $115, Maintains Equalweight Rating
2026-10-06 · Revvity to Host Investor Day
2026-10-06 · William Blair Initiates Revvity at Outperform
2026-10-02 · Revvity (RVTY) Upgraded to Buy: What Does It Mean for the Stock?
2026-10-02 · Revvity to Hold Earnings Call on November 3, 2026
2026-09-29 · Revvity (RVTY): Buy, Sell, or Hold Post Q2 Earnings?
2026-09-29 · Here's Why You Should Retain Revvity Stock in Your Portfolio for Now
2026-09-28 · 1 Unpopular Stock That Deserves Some Love and 2 Facing Headwinds
Price (daily)
Full chart · RSI · MACD · patterns